L. Fehrenbacher

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Roy S. Herbst, Diane Prager, Róbert Hermann et al. · Journal of Clinical Oncology · 2005 · 1.5K citations · Full text

Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study

Shirish M. Gadgeel, Rimas V. Lukas, Jerome H. Goldschmidt et al. · Lung Cancer · 2018 · 169 citations

Exploratory Analyses, Brain Metastases, Medicine +7

Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)

L. Fehrenbacher, RS Cecchini, CE Geyer et al. · Cancer Research · 2018 · 50 citations

Breast Oncology, Cancer Management, Adjuvant Chemotherapy +17

Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer

Gigi Chen, Minh Huynh, L. Fehrenbacher et al. · Journal of Clinical Oncology · 2009 · 49 citations · Full text

TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)

Roy S. Herbst, Diane Prager, Róbert Hermann et al. · Journal of Clinical Oncology · 2004 · 48 citations

Advanced Nsclc, Medicine, Cancer Management +15